Business Segment Prescription Products which generally require a prescription from a healthcare professional. Primary therapeutic areas are anti-inflammatories, immunosuppressants, hypothyroidism, anti-gout, analgesics, and corticosteroids. Overview Key Brands Revenue Performance Eltroxin Imuran Lipitor Lyrica Meticorten Purinethol Thyroid hormone Immunosuppressant Cardiovascular Anticonvulsantand neuropathy Corticosteroid Oncology Revenue by segment (%) 25% of Group revenue 36% of Group gross profit Africa Middle East 45 Australasia 39 Americas25 Asia6 Europe CIS6 Revenue Revenue 2024R’million 2023 R’million %ChangeReported CER Africa Middle East 4 242 3 876 9 9 Americas 2 832 1 801 57 42 Australasia 2 618 2 713 (4) (6) Europe CIS 991 989 – (7) Asia 697 542 29 24 Total 11 380 9 921 15 11 Gross profit (%) 60,9 60,7 Prescription brands achieved robust growth of 10% (16% CER), with revenue reaching R12 519 million. This growth was primarily driven by the Americas, which saw a 17% increase (34% CER) benefitting from the full year addition of the portfolio acquired in Latin America, which enjoyed double-digit growth on a comparable basis in H2 2025. Africa Middle East, the largest region within this segment, grew 8% with solid organic growth of 6% augmented by the Lilly franchise. Asia grew by 74% (78% CER), benefitting from the product swop with Sandoz. Solid Europe CIS growth of 5% (7% CER) was supported by core products, while Australasia experienced a 9% decline (-5% CER) due to further regulated price reductions in Australia.The gross profit margin rose to 61,8% (up from 60,9% in FY2024), with the positive impact of the favourable sales mix from Americas